PT - JOURNAL ARTICLE AU - Michael T. Meehan AU - Daniel G. Cocks AU - Jamie M. Caldwell AU - James M. Trauer AU - Adeshina I. Adekunle AU - Romain R. Ragonnet AU - Emma S. McBryde TI - Age-targeted dose allocation can halve COVID-19 vaccine requirements AID - 10.1101/2020.10.08.20208108 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.08.20208108 4099 - http://medrxiv.org/content/early/2020/10/11/2020.10.08.20208108.short 4100 - http://medrxiv.org/content/early/2020/10/11/2020.10.08.20208108.full AB - In anticipation of COVID-19 vaccine deployment, we use an age-structured mathematical model to investigate the benefits of optimizing age-specific dose allocation to suppress SARS-CoV-2 transmission. Across 179 countries, we find that the highest priority individuals are typically those between 30 and 59 years of age because of their high contact rates and higher risk of infection and disease. We reaffirm that vaccination alone may be insufficient to achieve herd immunity in some settings, and that additional intervention measures may be required. Nevertheless, we show that optimizing the allocation of vaccine doses can more than double their effectiveness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.M. is funded by a postdoctoral research fellowship from the National Health and Medical Research Council's Centre of Research Excellence in Tuberculosis Control on Both Sides of Our Border (Project ID: 1153493).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll input data and model source code has been deposited in a recognized public source repository (GitHub, https://github.com/michaeltmeehan/covid19).https://github.com/michaeltmeehan/covid19